Navigation Links
TB, HIV and malaria vaccine research gets major boost
Date:5/7/2013

Rockville, MD, US, Oxford, UK and Basel, Switzerland 7 May 2013 Aeras, a nonprofit biotech advancing TB vaccines for the world, the University of Oxford and Okairos, a biopharmaceutical company specializing in T-cell vaccines, today announced a $2.9 million grant to Aeras in support of a collaboration among the three parties to support the development of vaccines against tuberculosis, HIV and malaria.

The grant, provided by the Bill & Melinda Gates Foundation, allows the three groups to work together to develop scalable methods to enable large-scale production of multiple novel chimpanzee adenovirus vector constructs.

"We are pleased to expand our partnership with Okairos focusing on novel constructs utilizing chimpanzee adenovirus for next generation TB vaccines, as well as our collaboration with the University of Oxford, both of which are central to our organizational mission," said Tom Evans, MD, Interim CEO of Aeras. "This effort to improve optimization and scale up under current good manufacturing practices could also potentially benefit our peers in HIV and malaria vaccine development."

Novel constructs to be pursued include Okairos' proprietary technology platform that uses potent chimpanzee adenovirus vectors to stimulate robust T-cell and antibody responses against selected antigens.

Dr Riccardo Cortese, Chief Executive Officer of Okairos, said: "This new collaboration will enable us to advance our promising technology platform. By continuing to work with Aeras and Oxford, partners with proven expertise in vaccines development, we ultimately aim to deliver novel vaccines to developing countries where there is great need."

Aeras and Oxford both bring to the collaboration considerable expertise in vaccine development and manufacturing, with Oxford currently developing multiple vaccines, including vaccines against HIV, malaria and TB in clinical trials in the UK and Africa, and Aeras focusing primarily on tuberculosis vaccine research and development.

"Chimpanzee adenovirus-based vaccines have recently been shown to safely induce exceptionally potent cellular immunity in adults, children and infants, and are in clinical trials involving over 1,000 vaccinees in seven countries," commented Adrian Hill, Director of the Jenner Institute at Oxford University. "The diseases targeted, including malaria, HIV/AIDS and tuberculosis, are the greatest infectious killers of our time so this investment in manufacturing technology is very timely."


'/>"/>

Contact: Annmarie Leadman
aleadman@aeras.org
240-599-3018
Aeras
Source:Eurekalert

Related medicine news :

1. Detecting malaria early to save lives: New optical technique promises rapid and accurate diagnosis
2. New process would make anti-malarial drug less costly
3. UCI researchers create mosquitoes incapable of transmitting malaria
4. The math of malaria
5. Novel anti-malarial drug target identified
6. New research reveals extent of poor-quality antimalarial medicines in South American countries
7. BioMed Central presents Challenges in Malaria Research: Progress Towards Elimination
8. Novel technique demonstrates interactions between malaria parasite and HIV
9. Meddling with male malaria mosquito mating plug to control an epidemic
10. Protein impedes microcirculation of malaria-infected red blood cells
11. New opportunity for rapid treatment of malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Aerolib ... system for Clinical and Regulatory education for Physicians, Physician Advisors, Case managers, ... education methodology of Disease Specific Documentation Improvement. , The Aerolib Learning Management ...
(Date:1/19/2017)... ... ... cold weather here, many people will have to clear snow with snow blowers or shovels ... but they can be dangerous when used incorrectly. That’s why Amica Insurance is ... of snow blowers:, , When removing wet snow or debris from ...
(Date:1/19/2017)... ... January 19, 2017 , ... WhoHaha , a digital media company ... Heart Association (AHA) to produce a three-part video series that uses humor to highlight ... of the launch of AHA’s Healthy For Good™ movement, which is designed to inspire ...
(Date:1/19/2017)... Park City, Utah (PRWEB) , ... January 19, ... ... Sundance Film Festival in a medical capacity this year. Drs. Alexander Paziotopoulos, Andrew ... Lounge to provide a condensed version of the clinic’s leading recovery program. ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... provided a new $11,250,000 senior credit facility to Sunrise, Florida-based Management Health Systems, ... were used to facilitate a recapitalization of MedPro led by Harren Equity Partners. ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Marks E-QURE , s ... following similar agreements in Israel and Argentina ... 5 billion global market ... in medical devices for the treatment of advanced wound care, announced today it ... Colombia for the Company,s patented Bio-electrical Signal Therapy device ...
(Date:1/19/2017)... , Jan. 18, 2017   Synthetic ... clinical company developing therapeutics designed to preserve the ... patients, today confirmed plans to initiate a Phase ... modified-release reformulation of lovastatin lactone designed to reduce ... in the gut to treat the underlying ...
(Date:1/18/2017)... 18, 2017  EnteroMedics Inc. (NASDAQ: ... neuroblocking technology to treat obesity, metabolic diseases and ... an underwritten public offering of units for gross ... discounts and commissions and offering expenses payable by ... Class A Units, priced at a public offering ...
Breaking Medicine Technology: